A cDNA library was constructed from poly(A) + RNA isolated from the iododeoxyuridine-treated P3HR1 cell line. Five cDNA clones, which hybridized with the BamHI G fragment of Epstein-Barr virus (EBV) DNA, were subcloned and sequenced. Clones G2, G3 and G4 corresponded to the BGLF2 open reading frame (ORF) of EBV (B95-8, nucleotides 126837 to 125 866); G3 was found to contain the entire BGLF2 ORF. The predicted M, of the putative protein product of the EBV B95-8 BGLF20RF is 36K. Complete nucleotide sequencing of G3 revealed that there were two nucleotide changes from the reported sequence of the EBV B95-8 BGLF2 gene, but these did not alter the predicted amino acid sequence of the products. Clone G3 and a cDNA derived from it by N-terminal deletion were expressed in Escherichia coli, producing fusion proteins. Rabbit antisera against these proteins were shown to react with viral capsid antigen-expressing HR1 cells in an indirect immunofluorescence assay. In vitro transcription/translation products and fusion proteins expressed in E. coli were used to determine the presence of antibodies in sera from EBV-infected individuals. The results of immunoprecipitation and immunoblotting studies showed that the majority of EBV-seropositive individuals mount a serum antibody response to the BGLF20RF-encoded protein.
Introduction
Epstein-Barr virus (EBV), a human herpesvirus, causes infectious mononucleosis in normal adolescents (Henle & Henle, 1979) and B cell neoplasia in immunocompromised patients (Cleary et al., 1986) . Infection with EBV has been found to be closely associated with Burkitt's lymphoma (de The et al., 1978) and undifferentiated nasopharyngeal carcinoma (NPC) (de The & Geser, 1974) . The virus can be propagated in latently infected lymphoblastoid cell lines of human and marmoset origin. A small percentage of these cells spontaneously support the virus lytic cycle and the percentage of virusproducing cells can be increased by chemical induction using iododeoxyuridine (IdUrd), phorbol esters or n-butyric acid (Glaser et al., 1973; Luka et al., 1979; zur Hausen et al., 1978) .
The genome of EBV is a dsDNA molecule of approximately 170 kbp. The entire viral genome isolated from B95-8, a virus-producing cell line, has been cloned and sequenced (Dambaugh et al., 1980; Skare & Strominger, 1980; Baer et al., 1984) ; it contains at least 80 open reading frames (ORFs) , and approximately half of these have to some extent been studied and characterized. Several approaches have been used to study the minor proteins produced by EBV during virus replication. For example, monoclonal antibodies recognizing EBV-specific proteins have been used to identify their corresponding antigens (Balachandran et al., 1986; Oba & Hutt-Fletcher, 1988; Vroman et al., 1985) ; cDNA libraries constructed from various cell lines have been used to analyse several minor transcripts (Bodescot et al., 1984; Farrell, 1989; Laux et al., 1988; Manet et al., 1985; Pfitzner et al., 1987; Speck & Strominger, 1985) ; sequencing data (Baer et al., 1984) , as well as RNA mapping (Hummel & Kieff, 1982a) , and polypeptide mapping results (Cohen et al., 1984; Hummel & Kieff, 1982b) , have been used to predict potential ORFs.
Several viral proteins which are produced during the late stage of EBV replication have been identified. These proteins may be important for the penetration and release of EBV and therefore may be targets for the immune response. A virus capsid protein and four glycoproteins have been characterized as EBV late gene products and are specified by the following ORFs. BcLF1 encodes the major component of viral capsid antigen (VCA) (Vroman et al., 1985) ; BLLF1 encodes gp350/220 Hummel et al., 1984) , the virus attachment protein (Nemerow et al., 1987; Tanner al., 1987) ; BALF4 encodes gp I 10, a homologue of herpes simplex virus type 1 (HSV-1) glycoprotein B (Gong et al., 1987) ; BXLF2 encodes gp85 (Oba & Hutt-Fletcher, 1988) , a homologue of HSV-1 glycoprotein H; BILF2 encodes the gp78/55 molecule (Mackett et al., 1990) . Studies of these late antigen genes are helpful to the understanding of virus replication, the development of vaccines and the search for diagnostic markers specific for EBV-associated diseases.
Although human herpesviruses differ in many aspects, certain regions of their genomes are predicted to encode homologous counterparts (McGeoch, 1989) . A previous study has identified a 35K protein encoded in the EBV BamHI G region using hybrid-selected RNA from induced P3HR1 cells (Seibl & Wolf, 1985) . DNA sequences from other human herpesviruses predict a conserved ORF near this region (Lawrence et al., 1990) . We have characterized the EBV BamHI G region in detail (Chen et al., 1990) . Here, we report results of the cDNA cloning of several mRNA molecules complementary to the BamHI G fragment, and sequencing data from both the 5' and 3' termini of five cDNA clones. One of the clones, G3, containing the entire BGLF20RF, was subsequently subcloned and expressed in Escherichia coli. We have identified the BGLF2 gene product as a protein expressed late in EBV replication.
Methods
Cellculture and RNA preparation. P3HR 1 cells were grown at 37 °C in RPMI 1640 medium supplemented with 10~ foetal bovine serum (Gibco), 100 units/ml of penicillin and 100 gg/ml of streptomycin. The cell density was adjusted to 1 × 106/ml and IdUrd was added to a final concentration of 10 ~tg/ml to induce EBV replication. To inhibit virus DNA replication, and hence late transcription, phosphonoacetic acid (PAA) was added to a concentration of 1 mM at the same time as the IdUrd (Summers & Klein, 1976) , and incubation was continued at 37 °C for 72 h. Cellular RNA was extracted using the guanidinium/ caesium chloride method (Chirgwin et al., 1979) . Cells were washed with PBS and lysed in a 5 M-GTC solution (5 M-guanidinium thiocyanate, 25 mM-sodium citrate, 0'5~ Sarkosyl and 0.1~ 2-mercaptoethanol). The lysate (4 ml) was sheared by several passages through a 21-gauge needle, then overlaid onto a 1 ml cushion of 5.7 M-caesium chloride in centrifuge tubes. After centrifugation at 40000 r.p.m, in a Beckman SW50.1 rotor for 20 h, the RNA pellet was redissolved and the poly(A) ÷ RNA fraction selected by oligo(dT) column chromatography (Boehringer Mannheim) as described previously (Aviv & Leder, 1972) . Northern blot hybridization was performed as described by Thomas (1983) .
Construction and screening of the P3HR1 cell cDNA library. A cDNA library was constructed from poly(A) + RNA from IdUrd-treated P3HR1 cells in lambda gtl0 (Chen et al., 1990) . A total of 4 x 105 recombinants were screened using the EBV BamHI G fragment as a probe. Positive clones G2, G3, G4, G5 and BG12 (Fig. 1) were analysed further with BgllI-digested subfragments, and these cDNAs were subcloned into the EcoRI site of pGEM-4Z to generate pGEM-G2, pGEM-G3, pGEM-G4, pGEM-G5 and pGEM-BG12.
Nucleotide sequence analysis. Subcloned cDNA was sequenced from each terminus using T7 and SP6 primers. Sequencing was performed with a T7 DNA polymerase kit (Promega), which employed a modified chain termination method (Sanger et al., 1977) . HinclI-, PstI-, AccIand BglII-digested DNA fragments of clone G3 were subcloned into pGEM-4Z and sequenced from either end to obtain the entire nucleotide sequence.
In vitro transcription and translation, pGEM-G3, which has the BGLF20RF under the control of the T7 RNA promoter, was linearized with Ndel and used as a template for in vitro transcription. Transcription reactions were carried out as described (Chen et al., 1990) and, after removal of the template by DNase treatment, the RNA product was translated in rabbit reticulocyte lysates in the presence of [3sS]methionine (Chen et al., 1990) .
Immunoprecipitation. Serum (10 Ixl) from 12 healthy individuals with detectable antibody to EBV-specific VCA and from four NPC patients with very high anti-VCA antibody titres were incubated on ice with a 5 #1 aliquot of the in vitro translation product in the presence of PMSF (final concentration 1 ~tM) for 1 h. Protein A Sepharose (50 ~tl, 50 mg/ml; Pharmacia) in PBS was then added. The mixture was incubated on ice for an additional 30 min and then washed three times with NET buffer (150 mM-NaC1, 5 mM-EDTA, 50 mM-Tris-HCl, 0.2~ sodium azide, pH 7.4). After centrifugation of the antigen-antibody complex, the pellet was denatured with sample buffer (50 mM-Tris-HC1 pH 6.8, 2 mM-EDTA, 1~ SDS, 1~ 2-mercaptoethanol, 0.08~ bromophenol blue) and analysed by SDS-PAGE (Laemmli, 1970) and autoradiography.
Construction of BGLF2 expression plasmids and protein expression. A T7 phage-derived plasmid vector, pET3b (Rosenberg et al., 1987) , was used to express the BGLF2 ORF. Protein expressed from this construct consisted of the first 12 amino acids of the T7 phi 10 gene product fused to the BGLF2 translation product. A full-length EcoRI DNA fragment containing the BGLF2 ORF coding sequence and an AccI-EcoRI DNA fragment, encoding a truncated BGLF2 product (Fig. 2 ), were gel-purified, adapted with BamHI linkers and inserted into pET3b to generate pET3-G3 and pET3-G3.1, respectively. These two plasmids were introduced into E. coli BL21(DE3)pLysS (Studier et al., 1990) for the production of BGLF2 polypeptides. E. coli BL21 (DE3) harbouring the expression plasmids was grown and induced by adding 1 mM-IPTG as described previously (Linet al., 1987) . After induction for 3 h, bacterial cells were collected by centrifugation and resuspended in an equal volume of sample buffer. Lysed cells were analysed by SDS-PAGE. To radiolabel BGLF2 gene products, cultures were induced with IPTG, rifampicin was added to 200 ~tg/ml for 30 min and [3sS]methionine (5 gCi/ml) was then added for a further 10 rain before harvesting.
Preparation of fusion proteins for use as antigens. Cultures (500 ml) of BL21(DE3)pLysS harbouring BGLF2 ORF expression plasmids were grown and induced with IPTG. Cells were sedimented, washed and resuspended in 12 ml of lysis buffer (50 mM-Tris-HC1 pH 8-0, 2 mM-EDTA, 100 mM-NaC1) 3 h after induction. Lysozyme and sodium deoxycholate were added to the mixture to final concentrations of 1 mg/ml and 0.04~, respectively. The viscosity was reduced by sonication (Sonicator W-225R). This crude extract, which contained the insoluble fusion protein, was then centrifuged at 10000 r.p.m, for 15 min in a Sorvall SS-34 rotor. The pellet was washed several times with lysis buffer containing 0.2~ Triton X-100 and then resuspended in 4 ml of lysis buffer; an aliquot was subjected to SDS-PAGE. The BGLF2 fusion protein was excised from the gel and purified by electroelution and dialysis against PBS.
Immunization of animals. New Zealand white rabbits were immunized with emulsions made by mixing equal volumes of eluted protein (500 p.g) and Freund's adjuvant (Sigma) as described (Linet al., 1987) . The initial injection was followed by three booster injections subcutaneously every 4 weeks, and sera were collected 10 days later.
Western immunoblot analysis.
After SDS-PAGE, proteins were transferred to Immobilon-P (45 ~tm; Millipore). The membranes were cut into small strips and allowed to react with antiserum. Non-specific binding was prevented by incubation of the strips at 37 °C for 1 h with 3% bovine serum albumin (BSA) in Tris-buffered saline (TBS), pH 7-5. Strips were then incubated with test sera at a 1:100 dilution for 2 h at room temperature. After washing six times for 10 min in TBS, the strips were incubated with 1 × 105 c.p.m, of l:5I-labelled Protein A or goat anti-human IgG in BSA/TBS containing 0.05 ~ Tween 20 for 2 h. The strips were washed again, dried and subjected to autoradiography. lmmunofluorescence. Indirect immunofluorescence was performed using EBV VCA and EBV early antigen (EA) test slides, prepared from HR1 cells and chemically induced Raji cells, respectively (Gull Co.). A rabbit antiserum against the BGLF2 fusion protein or human sera from EBV-infected individuals was incubated with these slides for 1 h at 37 °C in a humidified atmosphere. The slides were then washed twice in PBS and subsequently incubated for 1 h at 37 °C with fluorescein isothiocyanate-conjugated goat anti-rabbit (or anti-human) antibody at a 1:20 dilution (Cappel). 
Isolation and mapping of cDNA clones
A eDNA library constructed from IdUrd-treated P3HR1 ceils was screened for EBV BamHI fragment G-specific clones. Approximately 4x 105 recombinant phage clones were analysed by hybridization with the BamHI G fragment of EBV derived from B95-8. Five positive clones, designated G2, G3, G4, G5 and BG12 (Fig. lc) , were characterized further by Southern hybridization using subfragments from BgllI-digested EBV BamHI fragment G as probes (Fig. l d) . The results are summarized in Fig. l(b and c) . BG12 [nucleotides 122156 to 122696 (B95-8 numbering system)] contained the 5' untranslated and N-terminal sequence of the B G L F 5 0 R F ; G5 (nucleotides 124551 to 125322) contained a portion of the BGRF1 ORF; G2, G3 and G4 were located at nucleotide positions 125824 to 126864, 125465 to 126913 and 125465 to 127371, respectively. These last three cDNA clones were all localized around the B G L F 2 0 R F . G3 and G4 contained the same polyadenylation signal and terminated at the same site, whereas G2 was truncated, with a deletion of the poly(A) region. G4 contained approximately one-third of the BGLF1 ORF in addition to the entire BGLF2 ORF and was presumably derived from a transcript initiated further upstream.
Analysis of the nucleotide sequence of G3
Clone G3, which encompassed the entire B G L F 2 0 R F , was sequenced completely using overlapping subclones. The entire sequence is given in Fig. 2 . The sequence of G3 (nucleotides 125 415 to 126 913) started 40 nucleotides before the B G L F 2 0 R F and finished 16 nucleotides downstream of the TATA promoter element at nucleotide 126929 (PI in Fig. 1 b) . This clone terminated 14 nucleotides after the polyadenylation signal. Comparison with the B G L F 2 0 R F of B95-8 EBV (positions 126837 to 125 866) revealed two nucleotide changes, at nucleotide 442 (position 126 472 of B95-8 EBV; T/G) and nucleotide 1068 (position 125 846; G/T). Since nucleotide 442 is the third base of a threonine codon and nucleotide 1068 is in the 3' untranslated region, the BGLF2 gene product of EBV from P3HR1 cells should be identical to that derived from B95-8 cells.
Northern hybridization analysis
To investigate transcription of the B G L F 2 0 R F , we performed Northern blot analysis using poly(A) ÷ RNA from IdUrd-treated P3HR1 cells and G3 cDNA as a probe. The results, shown in Fig. 3 , revealed two major transcripts of 1.7 kb and 4-1 kb, and three minor mRNAs of 1-9 kb, 2.6 kb and 3.2 kb (a, lane 1). To define further the temporal regulation of these transcripts during replication of EBV, PAA was included in the P3HR1 cell culture medium. Northern blot analysis indicated that 1.7 kb transcript was sensitive to treatment with PAA because it could not be detected in the PAA-treated preparation (a, lane 2). This implies that this G3-specific RNA may be a late EBV transcript. To characterize the 1-7 kb RNA further, we repeated the hybridization but probed with two subfragments of G3, a 0.3 kb BgllI-PvulI fragment (Fig. 1 d, probe A) and a 0.6 kb PvulI-BgllI fragment (Fig. 1 d, probe B) . Fig. 3 (b) shows that the RNA hybridizes strongly with the 0.3 kb probe Fig. l d) ; (c) a 0.6 kb PvulI-BgllI fragment (probe B in Fig. ld) . Two major transcripts of 4-1 kb and ~.7 kb and three minor transcripts of 1.9 kb, 2-6 kb and 3.2 kb are indicated.
(lane 1), but only weakly with the 0.6 kb probe (Fig. 3c , lane 1). These data are consistent with the hypothesis that the 1.7 kb transcript is that from which G3 was derived and may be initiated from the promoter at nucleotide 126929. The 4.1 kb RNA, perhaps the transcript from which G4 was derived, was relatively resistant to PAA (Fig.  3 a) . Three minor RNAs hybridized very faintly yet could be detected in repeated experiments (a, lane 1). Similar transcripts from near this region have also been demonstrated in RNA from EBV B95-8 by Farrell (Farrell, 1989; and personal communications) . These three minor transcripts require further investigation.
In vitro translation and immunoprecipitation G3-specific RNA was prepared by in vitro transcription using T7 RNA polymerase and pGEM-G3 as template. To determine whether G 3 cDNA contains a functionally complete gene, this RNA was translated using a rabbit reticulocyte lysate system. The major translation product (Fig. 4 , lane 2) exhibited an Mr of 36K, as predicted from the D N A sequence of ORF BGLF2. The 36K product was shown to react with antibodies from 16 individuals with specific anti-EBV VCA antibody titres in an immunoprecipitation assay (Fig. 4, lanes 8 to 19) . Moreover, sera from anti-VCA antibody negative individuals failed to react with the 36K protein in parallel experiments (Fig. 4, lanes 3 and 5 to 7) .
Expression of a BGLF2 fusion protein m E. coli
Expression plasmids containing full-length G3 c D N A (EcoRI fragment) and a truncated version with a deletion of the first 35 amino acid residues (AccI-EcoRI) (see Methods) were introduced into E. coli BL21(DE3)pLysS to generate three expression clones. For production of recombinant BGLF2 protein, the bacterial clones were grown and induced by the addition of IPTG. Fig. 5 (a) shows the Coomassie blue staining pattern of the recombinant BGLF2 protein produced by each construct. It appears that higher levels of the truncated BGLF2 fusion protein (lane 1) than of the full-length BGLF2 recombinant (36K) (lane 2) were produced. Expression of the BGLF2 fusion proteins could be assessed specifically by growing cultures in the presence of rifampicin, and determining [35S]methionine incorporation into the growing peptide chain due to expression by T7 RNA polymerase. As shown in Fig.  5(b) , labelled proteins of 29K (lane 1) and 36K (lane 2), corresponding to truncated and full-length BGLF2 fusion proteins, respectively, were produced from R N A synthesized from the T7 promoter by T7 R N A polymerase. Fig. 6 illustrates the use of bacterial fusion proteins as antigens for the detection of human antibodies specific for EBV using Western blot analysis. The partially purified, truncated BGLF2 fusion proteins were allowed methionine-labelled product expressed under the control of the T7 RNA promoter with the E. coli RNA polymerase inhibited by rifampicin. Lanes 1, proteins from E. coli expressing the truncated protein from pETG3.1 ; lanes 2, proteins from E. coli expressing the full-length BGLF2 product from pETG3; lanes 3, extracts from E. coli containing the pET3b vector as a control. Lane M, Mr markers. Recombinant proteins are indicated by arrowheads. Fig. 6 . Western blot analysis of antibodies that react with the truncated BGLF2 fusion protein. Partially purified BGLF2 protein prepared from E. coli was resolved on 10~ SDS-polyacrylamide gels and transferred to Immobilon-P. Strips cut from these blots were then incubated with 1 : 100 diluted sera from individuals containing different antibody titres against EBV VCA (lanes 1 and 2, 1 : 40; 3 and 4, 1 : 160; 5 and 6, 1:640; 7 and 8, sera from NPC patients; 9 and 10, anti-VCA antibody-negative sera). Lane 11, a negative control. Binding of antibody to strips was detected by 125I-labelled goat anti-human IgG, followed by autoradiography.
Western blot analysis of human antibodies against G3 product
to react with sera obtained from 10 individuals with variable antibody titres to EBV VCA. The results show that most of the EBV-seropositive individuals had antibodies which reacted with the B G L F 2 fusion proteins (lanes 1 to 8). The anti-BGLF2 protein antibody titres estimated from reactivity in Western blot assays did not always parallel the anti-VCA antibody titres determined by the immunofluorescence method commonly used in clinics.
Production o f antisera against the B G L F 2 product, and immunofluorescence
The full-length or truncated B G L F 2 recombinant proteins were purified further and used to generate hyperimmune rabbit sera as described in Methods. The reactivity of the rabbit polyclonal antiserum was determined by an immunofluorescence technique using commercial anti-EBV VCA-positive slides. As shown in Fig. 7 , a granular pattern of fluorescence was observed in nuclei using rabbit antiserum against the truncated B G L F 2 protein (c), although only about 2 to 5~ of the cells showed any fluorescence. The fluorescence appeared to be homogeneous in EBV-producing cells. A positive control is depicted in (a); this was labelled using a h u m a n antiserum to EBV-specific proteins. The number of fluorescence-positive cells was estimated to be between 10 and 13~o. The rabbit antisera did not react 
Discussion
In an attempt to characterize EBV-specific late gene products, we have isolated five distinct cDNA clones from a P3HRI cell-derived cDNA library. These cDNA clones correspond to transcripts located in the region around the BGLF4, BGLF5, BGLFI, BGLF2 and B G R F 1 0 R F s of EBV. When the DNA sequences of these five clones were aligned with those of B95-8 cellderived EBV counterparts, no splicing events were revealed. Northern hybridization of RNA from IdUrdtreated P3HR1 cells suggested vigorous transcription of the BamHI G fragment region of EBV during virus replication. Similar conclusions have been drawn from analyses of EBV of B95-8 origin (Farrell, 1989) . There appeared to be four nested RNA transcripts which were initiated from two overlapping transcription units in the BamHI G fragment region and terminated at the same polyadenylation signal (Farrell, 1989) . The 4.1 kb RNA detected by the G3 probe (Fig. 3 ) may be transcribed before ORF BDLF4, and the 1.7 kb RNA may be initiated from the promoter at nucleotide 126929 (P1 in Fig. 1 ). Our sequencing data from two cDNA clones, G4 and BG 12, corresponding to regions in the B G L F 2 0 R F plus a portion of ORF BGLF1, and portions of ORFs BGLF4 and BGLF5, respectively, were consistent with the hypothesis that the transcription pattern in the BamHI G fragment region of P3HRI cell-derived EBV is similar to that of EBV from B95-8 cells.
One of the cDNA clones, G3, contained the entire B G L F 2 0 R F . Alignment of the sequence of G3 and that published for EBV B95-8 showed the primary structure of both BGLF2 genes to be identical. We have also demonstrated a BGLF2-specific RNA transcript of around 1.7 kb in IdUrd-treated P3HR1 cells which was not detected in the same cells after treatment with PAA, which inhibits viral late gene transcription, indicating that ORF BGLF2 might specify a late gene product. A rabbit antiserum raised against an E. coli-derived BGLF2 fusion protein yielded homogeneous fluorescent staining on VCA-expressing HR1 cells, but not on EAexpressing cells. This further supports our hypothesis that ORF BGLF2 encodes a late protein. Using hybridselected translation for polypeptide mapping, Seibl & Wolf (1985) have demonstrated a 35K protein encoded by the EBV BamHI G fragment. The fact that both the in vitro translation products from clone G3 and the E. coli-derived BGLF2 recombinant proteins exhibited a mobility of approximately 36K on SDS-PAGE suggested that these proteins might be related.
We tested the possibility that the BGLF2 fusion protein might be suitable as a reagent for diagnosis of EBV infection. When immunoprecipitation was performed using the BGLF2 protein translated in vitro to detect EBV-specific antibodies in infected individuals (Fig. 4) , we found a correlation between the BGLF2 protein-specific antibody and anti-VCA antibody measured by indirect immunofluorescence, as commonly used in clinical diagnosis. Partially purified recombinant BGLF2 fusion proteins from E. coli can also be used for a similar purpose, as demonstrated by Western blot analysis (Fig. 6) . However, the anti-BGLF2 antibody titres estimated from Western blotting were not always consistent with those of anti-VCA antibody detected by indirect immunofluorescence. It remains to be determined whether such a test has any diagnostic value.
Computer-assisted analysis of the amino acid sequence of the BGLF2 gene product revealed a string of basic amino acids (KPKKKP, residues 65 to 70 of BGLF2), which could be a nuclear localization sequence. We used the EBML peptide databank to search for homologous protein sequences, but were unable to find any similar proteins. Recently, a portion of the DNA sequence of human herpesvirus 6 (HHV-6) was determined and compared with those of other human herpesviruses (Lawrence et al., 1990) . The BGLF20RF of EBV, llR ORF of HHV-6 and the UL16 ORF of HSV-1 share approximately 20~ nucleotide sequence identity. In particular, conserved cysteine arrangements are present in these three ORFs; six of 12 cysteine residues of the BGLF2 ORF were conserved in the l lR and UL16 ORFs, and an additional three cysteines were conserved in ORFs BGLFI and l lR (Fig. 2) . The conservation of these cysteine residues might imply that these proteins have similar structure-function relationships which will require further investigation.
